Advancing the outcome of advanced and metastatic bladder cancer

Poster Session 80

Monday 18 March 15:45 - 17:15

Location: Red Area, eURO Auditorium 2

Chairs: C. Beisland, Bergen (NO)  
Y. Loriot, Villejuif (FR)  
P. Patel, Birmingham (GB)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

16:08 - 16:13

State-of-the-art lecture The role of surgery and peri-operative systemic therapy
P. Patel, Birmingham (GB)

1114

Do urologists take the better slice of cake in muscle-invasive bladder cancer (MIBC)?

By: Dosanjh A.¹, Mintz H.P.², Mytton J.L.¹, Gallier S.¹, James N.D.³, Patel P.³
¹University Hospitals Birmingham NHS Foundation Trust, Dept. of Health Informatics, Birmingham, United Kingdom, ²University of Warwick, Warwick Medical School, Coventry, United Kingdom, ³University of Birmingham, Institute of Cancer and Genomic Sciences, Birmingham, United Kingdom

1115

Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histological subtype matter?

By: Berg S.¹, D’Andrea D.², Vetterlein M.W.³, Cole A.P.¹, Fletcher S.A.¹, Krimphove M.J.¹, Marchese M.¹, Lipsitz S.R.⁴, Sonpavde G.⁵, Noldus J.⁶, Shariat S.F.², Kibel A.S.¹, Trinh Q-D.¹, Mossanen M.¹
¹Brigham and Women's Hospital, Harvard Medical School, Division of Urologic Surgery and Center for Surgery and Public Health, Boston, United States of America, ²Medical University of Vienna, Dept. of Urology, Vienna, Austria, ³University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ⁴Brigham and Women's Hospital, Harvard Medical School, Division of Internal Medicine and Center for Surgery and Public Health, Boston, United States of America, ⁵Dana Farber Cancer Institute, Harvard Medical School, Dept. of Medical Oncology, Boston, United States of America, ⁶Marien Hospital Herne, Ruhr-University Bochum, Dept. of Urology and NeuroUrology, Herne, Germany

1116

Combination of the indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i) BMS-986205 with nivolumab (nivo): Updated safety across all tumors and efficacy in advanced bladder cancer (advBC) by patient (pt) subgroup
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1117</td>
<td>Combining DNA-repair gene mutations and molecular subtyping for more accurate prediction of outcome after neoadjuvant chemotherapy for bladder cancer</td>
<td>Batista Da Costa J., Seiler R., Ikeda K., Zhou J., Winters B., Gibb E., Volik S., Wright J., Sommerland M., Douglas J., Collins C., Black P.</td>
<td>University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, University of Bern, Dept. of Urology, Bern, Switzerland, University of Washington School of Medicine, Dept. of Urology, Seattle, United States of America, GenomeDX Biosciences, Dept. of R&amp;D, Vancouver, Canada, University Hospital of Southampton, Dept. of Urology, Southampton, United Kingdom</td>
</tr>
<tr>
<td>1118</td>
<td>Meta-analysis of prospective trials for bladder preserving tri-modal therapy in patients with muscle invasive bladder cancer</td>
<td>Inamoto T., Ibuki N., Komura K., Juri H., Yamamoto K., Yamamoto K., Narumi Y., Azuma H.</td>
<td>Osaka Medical College, Dept. of Urology, Takatsuki, Japan, Osaka Medical College, Dept. of Radiology, Takatsuki, Japan</td>
</tr>
<tr>
<td>1119</td>
<td>FIERCE-21: Phase 2 study of vofatamab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUCC)</td>
<td>Necchi A., Castellano D., Mellado B., Pang S.T., Urun Y., Park S.H.</td>
<td></td>
</tr>
</tbody>
</table>
Validation of the COBRA nomogram for the prediction of cancer specific survival in patients with bladder cancer treated with radical cystectomy

By: De Nunzio C.¹, Simone G.², Tuderti G.², Anceschi U.², Brassetti A.², Daneshmand S.³, Miranda G.³, Desai M.³, Gill I.³, Abol Enein H.⁴, Molinaro E.², Nacchia A.⁵, Lombardo R.⁵, Tema G.⁵, Leonardo C.⁶, Tubaro A.⁵
¹Sant'Andrea Hospital- "Sapienza" University, Dept. of Urology, Rome, Italy, ²Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ³University of Southern California, Dept. of Urology, Los Angeles, United States of America, ⁴Mansoura University, Dept. of Urology, Mansoura, Egypt, ⁵Sant'Andrea Hospital- , Dept. of Urology, Rome, Italy, ⁶Umberto I- "Sapienza" University, Dept. of Urology, Rome, Italy

Surgical outcome of pre-operative atezolizumab before radical cystectomy for muscle-invasive urothelial carcinoma of the bladder

By: Szabados B.¹, Duran I.², Crabb S.J.³, Van Der Heijden M.S.⁴, Font Pous A.⁵, Gravis G.⁶, Anido Herranz U.⁷, Protheroe A.⁸, Ravaud A.⁹, Maillet D.¹⁰, Mendez-Vidal M.J.¹¹, Suárez C.¹², Linch M.D.¹³, Prendergast A.¹, Mousa K.¹, Castellano D.E.¹⁴, Powles T.¹⁵, Rodriguez-Vida A.¹⁵
¹Queen Mary University of London, Barts Cancer Institute, London, United Kingdom, ²Hospital Universitario Marqués de Valdecilla, Dept. of Medical Oncology, Santander, Spain, ³University of Southampton, Southampton Clinical Trials Unit, Southampton, United Kingdom, ⁴Netherlands Cancer Institute, Dept. of Medical Oncology, Amsterdam, The Netherlands, ⁵Hospital Universitari Germans Trias i Pujol (HUGTIP), Institut Català d’Oncologia, Badalona, Spain, ⁶Institut Paoli-Calmettes, Dept. of Medical Oncology, Marseille, France, ⁷Hospital Clínico Universitario, Dept. of Medical Oncology, Santiago De Compostela, Spain, ⁸Churchill Hospital, Dept. of Medical Oncology, Oxford, United Kingdom, ⁹Hôpital Saint-André, Dept. of Medical Oncology, Bordeaux, France, ¹⁰Hosp Lyon SUD, Dept. of Medical Oncology, Lyon, France, ¹¹Reina Sofia University Hospital, Dept. of Medical Oncology, Cordoba, Spain, ¹²Vall d’ Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona, Spain, ¹³Royal Marsden Hospital, Dept. of Medical Oncology, London, United Kingdom, ¹⁴Hospital Universitario , Dept. of Medical Oncology, Madrid, Spain, ¹⁵Hospital Del Mar, Dept. of Medical Oncology, Barcelona, Spain

First survival outcomes and additional secondary analyses from PURE-01: Pembrolizumab (Pembro) before radical cystectomy (RC) in muscle-invasive urothelial bladder carcinoma (MIBC)
1123  **Antihypertensive drugs and risk of bladder cancer death in Finland**

By: Santala E.E. ¹, Kotsar A. ², Tammela T.L.J. ¹, Murtola T. ¹

¹University of Tampere, Faculty of Medicine and Life Sciences, Tampere, Finland, ²Tartu university Hospital, Dept. of Urology, Tartu, Estonia

1124  **Identification of stromal macrophage infiltration predict overall survival and recurrence-free survival in patients with muscle invasive bladder cancer**

By: Zhu Y., Zhang J., Gu C., Zhu Y., Ye D.

Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

17:01 - 17:08  **State-of-the-art lecture Current role of systemic therapy**

Y. Loriot, Villejuif (FR)